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Both Lipolysis and Hepatic Uptake of VLDL Are
Impaired in Transgenic Mice Coexpressing 
Human Apolipoprotein E*3Leiden and
Human Apolipoprotein Cl
Miek C. Jong, Vivian E.H. Dahlmans, Patrick J.J. van Gorp, Marco L. Breuer, Marc J.T.M. Mol,
André van der Zee, Rune R. Frants, Marten H. Hofker, Louis M. Havekes
Abstract Transgenic mice overexpressing human APOE*3- 
Leiden are highly susceptible to diet-induced hyperlipoprotein­
emia and atherosclerosis due to a defect in hepatic uptake of 
remnant lipoproteins. In addition to the human APOE*3Leiden 
gene, these mice carry the human APOC1 gene (APOE*3Leiden- 
Cl). To investigate the possible effect of simultaneous expression 
of the human APOC1 gene, we examined the phenotypic expres­
sion in these A POE* 3 Leiden- Cl mice in relation to trans­
genic mice expressing the APOi^Leiden gene without the 
APOC1 gene (APOE*3Leiden-HCR). APO£*3Leiden-Ci and 
APO^SLeiden-HCR mice had comparable liver expression 
for the AP0.E*3Leiden transgene and high total cholesterol levels 
on a sucrose-based diet compared with control mice (4.3 and 4.3 
versus 2.1 mmol/L). In addition, on this diet APOE*3L&iden-C 1 
mice displayed significantly higher serum triglyceride levels than 
APOE*3Leiden-HCR mice and control mice (4.4 versus 0.6 and
0.2 mmol/L). Elevated triglyceride and cholesterol levels were 
mainly in the VLDL-sized lipoproteins. In vivo turnover studies 
with endogenously triglyceride-labeled VLDL showed a reduced
VLDL triglyceride fractional catabolic rate for AP0£*3Leiden- 
C1 and APÒ-È^ Leiden-HCR mice compared with control mice 
(3.5 and 11.0 versus 20.4 pools per hour). To study whether the 
difference in fractional catabolic rates between the two transgenic 
strains was due to an inhibiting effect of apoCl on the extrahe­
patic lipolysis or hepatic-mediated uptake of VLDL, turnover ex­
periments were performed in functionally hepatectomized mice. 
Strikingly, both APOE*3h&iàe,x\-Cl and APOE*3Leiden-HCR 
mice showed a decreased lipolytic rate of VLDL triglyceride in 
the extrahepatic circulation compared with control mice (1.5 and 
1.8 versus 6.3 pools per hour). We conclude that next to an im­
paired hepatic uptake, overexpression of the APOiE^Leiden 
gene influences the extrahepatic lipolysis of VLDL triglycerides, 
whereas simultaneous overexpression of the APOC1 gene leads 
to a further decrease in hepatic clearance of VLDL. (Arterioscler 
Thromb Vase Biol 1996;16:934-940.)
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hyperlipoproteinemia transgenic mice
n humans carrying the APOE*3Leiden gene, the ac­
cumulation of chylomicron and VLDL remnant li­
poproteins in the circulation is inherited in a domi­
nant fashion . 1 The underlying mechanism is assumed to 
be a defect of this variant in binding to the hepatic lipo­
protein receptors. 2 We have studied3,4 the effect o f the 
apoE*3Leiden protein in lipoprotein metabolism in more 
detail by using transgenic mice expressing the human 
APOE*3Leiden gene. The high-expressing A P O E *3- 
Leiden transgenic mouse lines accumulate rem nant li­
poproteins in the plasma and develop atherosclerotic 
lesions, especially after consuming fat- and choles- 
terol-containing diets. As expected, in vivo VLDL- 
apoB turnover studies show that the hypercholesterol­
emia in these mice is indeed due to a defect in hepatic 
uptake of remnant lipoproteins . 5
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Since at the time of the generation of these mice the 
exact location of the HCR of the APOE  gene was un­
known, except that it lies about 9 kb downstream of the 
APOC1 gene , 6 we used a 27-kb DNA construct covering 
the APOE*3Leiden and APOC1  genes and the HCR el­
ement. Western blot analysis showed that these APOE*3- 
Leiden transgenic mice express both genes (designated 
APO-E^Leiden-Ci transgenics) . 3 Thus, we cannot ex­
clude that the hyperlipidemia and atherosclerosis ob­
served in these transgenic mice is (partly) due to the 
coexpression of the human APOC1 gene.
Little is known about the in vivo function of the apoCl 
protein, although in vitro studies have shown that apoCl 
can inhibit the LPL-mediated hydrolysis of VLDL TGs . 7,8 
Studies involving the addition of purified human apoCl 
to chylomicrons9 and TG emulsions10 show inhibition of 
their uptake by perfused rat livers. Furthermore, apoCl 
prevents apoE-mediated VLDL binding to the LDL re­
ceptor11 and the LDL receptor-related protein in vi­
tro , 12,13 presumably by displacing apoE from the VLDL 
particle. 14
The observation that transgenic mice with high liver- 
specific expression of the human APOC1 gene exhibit 
hypertriglyceridemia15 suggests that a direct inhibiting ef­
fect of apoC 1 on either apoE-mediated remnant clearance 
or VLDL TG lipolysis holds true for the in vivo situation 
as well. However, such a role for apoCl could not be 
deduced from the results we obtained with A p o C l-defi-
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Selected Abbreviations and Acronyms
FCR = fractional catabolic rate 
FF A = free fatty acid 
HCR = hepatic control region 
HFC = high fat/high cholesterol 
Km = Michaelis-Menten constant 
LFC = low fat/low cholesterol 
LPL = lipoprotein lipase 
LR = lipolytic rate 
PAGE = polyacrylamide gel electrophoresis 
SDS = sodium dodecyl sulfate 
SR = secretion rate 
SRM-A = standard rat mouse 
TG = triglyceride 
Vmax ~ maximal enzyme activity
cient mice . 16 Although a lower level of plasma lipids was 
expected in these mice, we observed that mice with total 
apoC 1 deficiency have normal plasma cholesterol levels 
on a regular chow diet, whereas after a severely hyper- 
cholesterolemic diet, A p o C l-deficient mice exhibit mildly 
elevated plasma cholesterol levels. Thus, the exact role 
apoCl plays in remnant lipoprotein metabolism in vivo 
cannot be deduced from these studies with genetically 
modified mice.
In the present article we report on our study of the effect 
of APOC1 gene coexpression on the phenotype of APOE* 3- 
Leiden transgenic mice by comparing the APOE*3Leiden- 
C1 mice described above with transgenic mice carrying only 
the ÆPŒ*3Leiden gene directly linked to the HCR ele­
ment, thus without coexpressing the APOC1 gene (desig­
nated APOis^Leiden-HCR transgenics). By performing in 
vivo turnover studies with autologous TG-labeled VLDL 
samples, we found that additional apoCl protein indeed in­
hibits the hepatic uptake of remnant lipoproteins in vivo, 
whereas apoCl does not inhibit VLDL TG lipolysis. More 
strikingly, besides an inhibitory effect on hepatic uptake, we 
found that enrichment of VLDL particles with the apoE*3- 
Leiden protein also resulted in a disturbed extrahepatic 
lipolysis of VLDL TGs.
Methods
DNA Construct
The APO¿¿*3Leiden-HCR construct was generated from plas­
mid pJS276 (kindly provided by Dr J.D. Smith, Rockefeller Uni­
versity, New York, NY), which carries both the APOE*3 gene 
(from the —650-bp Bgl II site to the 1.9-kb //indili site) and a 
5.5-kb BamHl fragment from the 5' region of APOC1', including 
the HCR. 17 The APOE* 3Leiden gene was introduced into pJS276 
by exchanging a 2-kb EcöRI fragment encompassing exon 4 of 
the APOE*3 gene with the similar fragment from a cosmid car­
rying APOE*3Leiden. The resulting insert (APOE* 3Leiden- 
HCR) was excised from the plasmid by using the restriction en­
zymes Kpn I and HinäSl.
Generation and Analysis of Transgenic Mice
APO£*3Leiden-Ci mice were generated previously. 3,4 Trans­
genic and nontransgenic littermates were obtained by breeding 
with C57BL/6J mice. Mice of the F7 generation were used for 
the present experiments.
APOE* 3Leiden-HCR mice were generated according to the 
method of Hogan et al18 with some minor modifications. In brief, 
a DNA solution was microinjected into male pronuclei of fertil­
ized mouse eggs taken from superovulated FI (C57BL/6J*CBA/ 
J) females. Transgenic offspring were identified by polymerase 
chain reaction analysis and Southern blot analysis on genomic 
tail-derived DNA. 3 Six founders were obtained from which one
line with high liver expression of the APOE*3Leiden transgene 
was bred with C57BL/6J mice. Mice of the F4 generation were 
used for the experiments.
All mice in this study were females housed under standard 
conditions with free access to water and food. Nontransgenic 
littermates were used as a control group. All experiments were 
performed at 1 p m  with food withdrawn at 9 a m .
Northern Blot Analysis
Transgenic mice were anesthetized with an intraperitoneal in­
jection of 0.5 mL/kg Hypnorm (Janssen Pharmaceutical) and 12.5 
mg/kg midazolam (Roche Netherlands bv), and the livers were 
excised for quantification of APOE* 3 Leiden and APOC I mRNA. 
Total RNA was isolated from liver by using the RNAZOL pro­
cedure (Cinna/Biotecx). RNA samples (7.5 jàg per lane) were 
separated by electrophoresis through a denaturing agarose gel 
(1% wt/vol) containing 7.5% formaldehyde and were transferred 
to a nylon membrane (Hybond N, Amersham) according to the 
manufacturer’s recommendations. Blots were subsequently hy­
bridized with 32P-labeled probes of human APOE cDNA, human 
APOC1 cDNA, 19 mouse ApoCl cDNA, 20 and a rat GAPDH 
cDNA21 in a solution containing 50% formamide. The intensity 
of the hybridization signal was quantified by using a Phosphor 
Imager (Molecular Dynamics). The amounts of APOE*3Leiden 
and APOC1 mRNA were related to the level of GAPDH mRNA.
Diets and Dietary Treatment
After weaning at 28 days of age, mice were fed an SRM-A 
(chow) diet. After 7 weeks of age, two different diets (Hope 
Farms) were administered to groups of each strain (at least eight 
mice per group). These diets were semisynthetic and composed 
essentially according to Nishina et al. 22 First, mice were fed 
an LFC diet containing 50.5% sucrose, 12.2% com starch, 5% 
com oil, and 5% cellulose (by weight) 4 for 3 weeks. Thereafter, 
the same mice were fed an HFC diet for 3 weeks containing 
15% cocoa butter, 0.25% cholesterol, and 40.5% sucrose (by 
weight) . 23 After each dietary treatment, 100 (iL whole blood was 
obtained from each fasting mouse via tail bleeding.
Analysis of Lipids and Lipoproteins
Levels of total serum cholesterol, serum TGs (without free 
glycerol), and FFAs were determined enzymatically by using 
commercially available kits (No. 236691 [Boehringer Mannheim 
GmbH], No. 337-B [Sigma GPO-Trinder kit], and a Nefa-C kit 
[Wako Chemicals GmbH], respectively).
For fast protein liquid chromatography fractionation of lipo­
proteins, 2 0 0  /iL pooled serum from at least eight fasted mice per 
group was injected onto a 25-mL Superose 6  preparation-grade 
column (Pharmacia) and eluted at a constant flow rate of 0.5 mL/ 
min with phosphate-buffered saline, pH 7.4. Fractions of 0.5 mL 
were collected and assayed for cholesterol and TG levels as de­
scribed above.
Protein concentrations in lipoprotein fractions were determined 
by using the method of Lowry et al24 with bovine serum albumin 
as a standard.
VLDL fractions (¿<1.006 g/mL) were isolated from the 
pooled serum of at least 1 0  mice by ultracentrifugation at 40 0 0 0  
rpm in an SW-40 swingout rotor (Beckman) for 18 hours at 5°C.
Quantification of Human ApoE
Serum human apoE*3Leiden concentrations were measured by 
using a sandwich enzyme-linked immunosorbent assay. 4 Affin­
ity-purified polyclonal goat anti-human apoE antibodies were 
used for coating, and polyclonal rabbit anti-human apoE was used 
as the secondary antibody. After incubation of the plates with 
swine anti-rabbit IgG antibodies conjugated to horseradish per­
oxidase, detection was done by the immunoperoxidase procedure 
using tetramethylbenzidine as substrate. Pooled plasma from 
healthy human subjects with known apoE levels was used as a 
standard.
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Fig 1. Schematic representa­
tion of the APOE-APOC1 gene 
cluster. Top, 27-kb construct 
used for the APOf*3Leiden-C7 
(E*3L-C1) transgenic mice. Bot­
tom, 11 -kb construct used for the 
APOP3Leiden-HCR (E*3L-HCR) 
transgenic mice. Open boxes in­
dicate genes; black boxes, the 
HCR.
SDS-PAGE and W estern Blot Analysis
From each lipoprotein fraction, 1.5-fj.g protein samples were 
analyzed for apolipoproteins by using SDS-PAGE with 4% to 
2 0 % gradient gels. Proteins were either stained with Serva blue 
R or transferred to nitrocellulose membranes (Schleicher and 
Schuell) followed by incubation with polyclonal rabbit antisera 
against mouse apoCl or apoE and human apoCl or apoE. Goat 
anti-rabbit IgG conjugated to peroxidase (Nordic Immunology) 
was used as the secondary antibody, and detection was done by 
using the immunoperoxidase procedure with 4-chloro-1 -naphthol 
as substrate.
P reparation  of Endogenously Labeled VLDL
Fasted mice were anesthetized with 0.5 mL/kg IP hypnorm 
(Janssen Pharmaceutica) and 12.5 mg/kg IP midazolam (Roche). 
Body temperature was maintained with the use of heat lamps. 
[3H]palmi tate dissolved in ethanol (Amersham) was evaporated 
under nitrogen and redissolved in 0.9% NaCl containing 2  mg/ 
mL bovine serum albumin. Mice were injected intravenously via 
the tail vein with 100 ¿¿Ci of the prepared [3H]paImitate. To de­
termine the efficiency of the in vivo [3H]palmitate incorporation 
into VLDL TGs, 50-fj.L blood samples were drawn at 2, 10, 20, 
30, and 60 minutes after the [3H]palmitate injection. Lipids were 
extracted from the serum according to the method of Bligh and 
Dyer, 25 and the amount of radioactivity in the TG fraction was 
determined after separation of the TGs from the other lipid com­
ponents by using thin-layer chromatography on silica gel 60 
plates (Merck) with hexane/diethylether/acetic acid (83:16:1, voi/ 
vol/vol) as resolving solution. [,4C]tripalmitate (Amersham) was 
used as an internal standard, and the proportion of the radioac­
tivity in the plasma TG fraction was calculated in relation to the 
body mass of the mice.26 To obtain VLDL radiolabeled in its TG 
moiety, anesthetized mice were injected as described above and 
bled from the retro-orbital plexus 25 minutes after injection. Ra­
diolabeled VLDL (d<  1.006 g/mL) used for clearance studies was 
isolated from the serum of six mice per group by using ultracen­
trifugation. These VLDL samples were dialyzed against phos­
phate-buffered saline, pH 7.4, at 4°C and subjected to lipid ex­
traction and thin-layer chromatography analysis. In all the VLDL 
fractions used, >95% of the radioactive label was bound to TGs.
In Vivo Turnover Studies Using 
[3H]TG-Labeled VLDL 
Whole Animal
To study the in vivo clearance of labeled VLDL TGs due to 
both peripheral lipolysis and hepatic uptake of the remnant par­
ticle, fasted mice were anesthetized and injected intravenously 
with 80 000 dpm [3H]TG-labeled VLDL (autologous injections). 
The disappearance of the radiolabeled VLDL was determined 
from 40-juL blood samples drawn at times after the injection as 
indicated. Total plasma radioactivity was used to represent VLDL 
TG radioactivity, as a pilot study showed that the disappearance 
of radioactivity as measured after lipid extraction followed by 
thin-layer chromatography TG analysis did not differ from the 
disappearance of total plasma radioactivity (not shown). The ra­
dioactivity at each time point was multiplied by the plasma vol­
ume of the animal26 and divided by the injected dose. The data
were modeled by a biexponential curve from which the FCR was 
calculated by using the reciprocal area under the curve. The SR 
was calculated by multiplying the FCR by the plasma VLDL TG 
pool size as measured in each mouse during the experiment.
Functionally Hepatectomized Animal
To investigate the in vivo clearance of radiolabeled VLDL due 
to peripheral lipolysis only, mice were functionally hepatecto­
mized to exclude hepatic VLDL TG production and uptake. 27 
Mice were anesthetized, and the hepatic portal vein and the he­
patic artery were ligated prior to injections. [•’HJTG-labeled 
VLDL was injected, and blood samples were drawn and analyzed 
as described above. The data were kinetically modeled to cal­
culate the LR by using the reciprocal area under the curve. To 
ensure total exclusion of the liver from the circulation, liver ra­
dioactivity was measured at the end of the experiment by using 
a sample oxidizer (Packard Instrument Co). For each hepatecto­
mized mouse used in this study <0.5% of the injected dose was 
found in the liver.
In Vivo Hepatic VLDL TG Production by T riton 
WR1339 Injection
Fasted mice were injected with Triton WR1339 (500 mg/kg 
body wt IV) by using a 15% (wt/vol) Triton solution in 0.9% 
NaCl. Plasma VLDL clearance is virtually completely inhibited 
under these circumstances. 28 Blood samples were drawn at ap­
propriate times (up to 60 minutes) after the Triton WR1339 in­
jection. TGs were measured in the plasma and related to the body 
mass of the mice as described above. Production of hepatic TGs 
was calculated from the slope of the curve and expressed as milli­
moles per hour per kilogram body weight.
LPL-Mediated In Vitro Lipolysis of VLDL
In vitro lipolysis assays with isolated VLDL fractions (d< 
1.006 g/mL) were performed at 37°C in a 0.1-mol/L Tris buffer, 
pH 8.5, for 10 minutes with commercially available LPL (Sigma) 
in the presence of 2% (wt/vol) essentially FFA-free albumin. The 
reaction was stopped by adding stop buffer containing 50 mmol/ 
L KH2PO4 and 0.1% Triton X-100, pH 6.9, and placed on ice. 
To obtain a time zero control, the reaction was prevented by 
adding stop buffer prior to adding LPL and placed on ice. FF As 
were measured as described above. The rate of FFA release by 
LPL was linear for the 10 minutes used in this assay. The assay 
was performed on five different VLDL concentrations (<¿<1.006 
g/mL) in the range of 0.05 to 0.5 mmol/L with duplication of 
FFA determination. Apparent Km and Vmax of VLDL as substrate 
for LPL were calculated from Lineweaver-Burk plots.
Results
Characterization of A P O i^ L e id e n -H C R  and 
AP02£*3Leiden-C/ Mice
Six founder mice carrying the APOB^Leiden-HCR 
construct (Fig 1 ) were generated. Two strains showed 
high-level expression in the liver. For the present study 
one of these strains was further characterized that showed 
hepatic A PO i^L eiden mRNA levels comparable with the
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previously generateci APOE*3\-,&iden-Cl mice of line 2 
(Table 1 ). In addition, APOE*3Leiden-C l  mice also ex­
hibited hepatic expression of human APOC1 mRNA , 3 
whereas the hepatic mouse A poC l mRNA levels of 
APOE*3Leiden-HCR and AP0£*3Leiden-C7 mice did 
not differ from that of control mice (99 ±25% and
109±26% of control value).
Human apoE*3Leiden levels, as quantified in individual 
mouse serum, were significantly elevated in APOE*3Lei- 
den-Cy mice compared with A PO i^Leiden-H C R  mice 
(Table 1 ). The two transgenic mouse strains were further 
characterized by analyzing the apolipoprotein composition
of VLDL fractions (¿<1.006 g/mL). SDS-PAGE and 
Western blot analysis showed that both strains had equal 
amounts of human apoE*3Leiden protein on VLDL (Fig 
2 a). The amount of mouse apoE on VLDL was similar in 
both APOE*3Leiden-HCR and APOE*3heiden~Cl mice 
compared with control mice (Fig 2b). As expected, human 
apoCl was found only onAPOE*3Leiden~Cl VLDL (Fig 
2c). Furthermore, mouse apoCl (showing cross-reactivity 
with mouse apoC3) did not differ between APOE*3Lei- 
den-HCR, APOE*3Leide,n-Cl, and control mice (Fig 2d). 
Serva blue R staining showed that the total amount of apoE 
was increased «twofold in both AP(?£'*3Leiden-HCR and 
APOE*3L,&id&n-C 1 mice compared with control mice (Fig 
2e). Analysis of the lipid composition of APOE*3Leiden- 
HCR and APOE*3Leiden-CJ VLDL revealed no differ­
ences (not shown).
Serum lipids were measured in fasting transgenic mice 
and nontransgenic littermates as control animals. When 
kept on an SRM-A chow diet, both APOE*3L&iden-Cl 
and APOE^Leiden-HCR mice showed significantly ele­
vated levels of serum cholesterol compared with control 
mice. Furthermore, serum TG levels were significantly el­
evated, being most pronounced in APOE*3Leiden-Cl 
mice (Table 1 ).
Feeding sucrose is known to stimulate hepatic VLDL 
TG production. 22 To investigate the response of both trans­
genic mouse lines to a sucrose-rich diet, mice were fed an 
LFC diet containing 50.5% sucrose. After 3 weeks on the 
LFC diet, the total serum cholesterol levels of both 
APOE*3L,eiden-Cl and APOÆ^Leiden-HCR mice were 
elevated compared with their respective levels on the 
SRM-A diet and significantly different from control mice. 
In addition, upon sucrose feeding the serum TG level fur­
ther increased in APOE*3Leid&n-Cl mice, whereas, re­
markably, it remained unaltered in APOE* 3 Lei den-HCR 
mice (Table 1). This increase in serum TGs for 
APO£*3Leiden-C7 mice was confined to the VLDL-sized
(a) Human E (b) Mouse E
1 2 3 1 2 3
(c) Human C1 (d) Mouse C1
1 2 3 1 2 3
(e) Total E
1 2 3
Fig 2. Western blot analyses of mouse lipoproteins. VLDL 
(d< 1.006 g/mL) was isolated by ultracentrifugation from the 
pooled serum of 9 control (lane 1), 9 /4PO£*3Lelden-HCR (lane 
2), and 9 APO£*3Leiden-C7 (lane 3) fasted mice. VLDL protein 
(7.5 //g) was subjected to SDS-PAGE (4% to 20% gradient gels) 
and transferred to a nitrocellulose membrane. The membrane 
was incubated with polyclonal antisera against human apoE (a), 
mouse apoE (b), human apoCl (c), or mouse apoCl (d). Total 
apoE was stained with Serva blue R (e). Note the double band 
In d, which is due to cross-reactivity of the mouse apoCl anti­
serum with mouse apoC3.
fractions as determined by fast protein liquid—Superose 6  
chromatography (not shown).
We also compared both transgenic lines and control 
mice regarding their response to cholesterol feeding. After 
3 weeks on the HFC diet (0.25% cholesterol), total serum 
cholesterol levels were increased among all groups com­
pared with the LFC and SRM-A diets but were more pro­
nounced in the transgenic mice. Serum TG levels in the 
APOE*3Leiden-C l mice were lower on the HFC diet 
than on the SRM-A and LFC diets . 4 TG levels in 
A PO ü^Leiden-H CR and control mice remained un­
changed upon cholesterol feeding (Table 1).
TG Turnover Studies in AP0Z?*3Leiden Transgenic 
and Control Mice
To investigate the mechanisms underlying the pronounced 
hypertriglyceridemia in APOE* 3 Leiden-C1 mice relative to 
APOZr^SLeiden-HCR and control mice, we performed 
VLDL TG turnover studies. Prior to these experiments, all 
mice were fed for 3 weeks with the sucrose-containing LFC 
diet because the hypertriglyceridemia of AP02iif!3Leiden-C/ 
mice was most pronounced when fed this diet.
T a b l e  1. Characterization of APOE*3Le¡den and Control Mice
Mouse
Strain
ApoE*3Leiden
mRNA in Protein in 
Liver, % Serum, mg/dL
Diet
SRM-A LFC HFC
TC TG TC TG TC TG
E*3L-C1 100+30 53±13f 3.0+0.6* 1.9+0.6*f 4.3+0.9* 4.4+1.1*t 8.5±1.1*t 1.3±0.7*
E*3L-HCR 110+25 35+11 2.8+0.6* 0.8±0.3* 4.3+0.6* 0.6±0.2* 6.8+0.6* 0.6+0.4*
Control IMD ND 1.8+0.1 0.4+0.1 2.1 ±0.4 0.2+0.2 2.8±0.3 0.2+0.1
mRNA concentrations are relative to an internal standard GAPDH and are expressed as a percentage oMPOP3Leiden- 
C1 mice. Human apoE*3Leiden was quantified in mouse serum by using a sandwich enzyme-linked immunosorbent assay. 
Values for mRNA and protein are from mice fed SRM-A chow. Total cholesterol (TC) and TG values are expressed in 
millimoles per liter and were measured in serum of >4POE*3Leiden and control mice fed an SRM-A chow, LFC, or HFC diet 
for 3 weeks. Values for all measurements are mean±SD (n=8 mice/group). *P<.05 control vs transgenic animals on the 
same diet; 1P<.05 /4POP3Leiden-C7 (E*3L-C1) vs /4POP3Leiden-HCR (E‘3L-HCR) on the same diet by nonparametric 
Mann-Whitney U test. ND indicates not detectable.
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Fig 3. Line graph shows TG turnover studies in APOE*3Leiden- 
C1 (•), APOP3Leiden-HCR (O), and control (+) mice. Mice fed 
the LFC diet for 3 weeks were fasted and injected intravenously 
with 100 fiCi [3H]palmitate. The appearance of the label in plasma 
TGs over time was expressed as a percentage of the injected 
dose (see “Methods”). Each point represents mean±SD for six 
mice per group.
APOE*3Leiden-C l, APO£*3Leiden-HCR, and control 
mice were injected with [3H]palmitate, and the appearance 
of label in plasma TGs was followed over time. Almost all 
the [3H]palmitate (99.4%) was cleared from the plasma for 
all groups 2 minutes after injection (results not shown). The 
initial rate of appearance in the plasma of 3H-labeled TGs 
was similar for both transgenic and control mice (Fig 3). 
However, the larger area under the curve suggests that clear­
ance from the plasma was delayed in APOE*3Leiden-Cl 
mice compared with APOE* 3Leiden-HCR and control mice.
Endogenously labeled VLDL (d<  1.006 g/mL) was iso­
lated from serum collected from mice 25 minutes after 
[3H]palmitate injection. After autologous injection, the la­
beled VLDL TGs were cleared at a reduced rate in 
APOE*3L&id&n-Cl mice compared with AP0.E*3Leiden- 
HCR and control mice (34% versus 14% and 7% of the 
injected dose was still present in the plasma 12.5 minutes 
after injection; Fig 4). From these data the FCRs and SRs
Table 2. VLDL TG FCRs, SRs, and LRs for 
APOE*3Leiden and Control Mice
Mouse
Strain
FCR,
pool/h
P3L-C1
E*3L-HCR
Control
3.5±0.3*t 
11.0±1.8* 
20.4±3.2
SR,
mmol • h 1 • kg 1
0.28 ' 0.07 
0.26±0.08 
0.17±0.04
LR, 
pool/h
1 .5 '0 .9  
1.8 ' 1.1 
6.3 ±2.1
FCRs were calculated from in vivo clearance studies of labeled autol­
ogous VLDL in transgenic and control mice (Fig 4), From these date SRs 
were calculated by multiplying the FCR by the pool size. LRs were cal­
culated from the in vivo clearance of labeled VLDL in hepatectomlzed 
transgenic and control mice (Fig 5). Values are mean±SD (n«7 mice/ 
group). *P<.05 control vs transgenic mice; tP<«05 APOE*SLQ\ä&r\«C1 
(E*3L-C1) vs /\POP3Leiden-HCR (E"3L-HCR) by nonparametrlc Mann- 
Whitney U test.
«m
were calculated (Table 2). In A P OE* 3  Lei de n- C l  and 
APOE*3Leiden-HCR mice the VLDL FCRs were signif­
icantly decreased compared with that in control mice (3.5 
and 11.0 versus 20.4 pools per hour).
VLDL SRs were significantly elevated
APOE*3Leiden-Ci and A P0£*3Leiden-H CR mice com
pared with control mice (Table 2). Direct assessment of 
the in vivo VLDL TG production rate by injecting Triton 
WR1339 gave similar results (0.23±0.10, 0.17±0.07, and 
0.14±0.08 mmol ■ h “ 1 • kg ' 1 for A PO E^Leiden-H C R , 
APOE*3Leiden-C l , and control mice, respectively). 
These differences in VLDL production rate were not 
highly significant and can only partly explain the strongly 
decreased FCRs observed in both transgenic mouse lines.
The VLDL TG FCR in AP<9£*3Leiden-C7 mice was 
much lower than that in AP<9£*3Leiden-HCR mice (3.5 
versus 1 1 . 0  pools per hour). A  disturbed extrahepatic LPL- 
mediated lipolysis in the AP<9£*3Leiden-C/ mice could 
explain this difference. To test this hypothesis, control and 
transgenic mice were functionally hepatectomized to rule 
out VLDL TG clearance via the liver lipoprotein receptors. 
The rate of clearance from the extrahepatic circulation of 
[3H]TG-labeled autologous VLDL was hampered in both 
transgenic lines compared w ith control mice (Fig 5), By 
calculating the LR from these experiments, we could ob­
serve no significant difference between the two transgenic
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Fig 4. Line graph shows clearance of labeled VLDL in 
APOP3Leiden-C7 (•), APO£*3Leiden-HCR (o), and control (+) 
mice. Mice fed the LFC diet for 3 weeks were fasted and injected 
intravenously with 80 000 dpm in vivo labeled autologous VLDL. 
The disappearance of the labeled VLDL was followed by counting 
the plasma radioactivity expressed as the percentage of the in­
jected dose. Values are mean±SD for seven mice per group.
Curves were calculated from the mean data by using a biex­
ponential curve fit model.
Time (min)
Fig 5. Line graph shows clearance of labeled VLDL in 
APOP3Leiden-C7 (•), APOP3Lelden-HCR (O), and control (+) 
mice. Mice fed the LFC diet for 3 weeks were functionally he­
patectomized, and 80 000 dpm in vivo labeled autologous VLDL 
was injected. The disappearance of the labeled VLDL was fol­
lowed by counting the plasma radioactivity expressed as the 
percentage of the injected dose. Values are mean±SD for seven
mice per group. Curves were calculated from the mean data by 
using a biexponential curve fit model.
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mouse strains. However, the LRs of both APO-Z^Leiden- 
HCR and APOE*3Leiden-Cl mice were significantly 
lower than that of control mice (1.8 and 1.5 versus 6.3 
pools per hour; Table 2).
These results indicate that the presence of human 
apoE*3Leiden on the VLDL particle inhibits the lipolysis 
of VLDL TGs in the extrahepatic circulation in vivo. How­
ever, this is not true for in vitro lipolysis. Lineweaver-Burk 
plot analysis with VLDL samples (d <  1.006 g/mL) iso­
lated by ultracentrifugation from pooled serum from 
APOE*3Leiden-C l , APOE*3Leiden-HCR, and control 
mice revealed no differences among the different VLDL 
samples in suitability as substrate for LPL in vitro. No 
significant differences could be observed between the re­
spective VLDL samples in both the apparent Km and V 
values (Table 3).
Discussion
From our previous findings with AP0I?*3Leiden trans­
genic mice we cannot definitely conclude that the observed 
hyperlipidemia and atherosclerosis in these mice is due 
exclusively to the expression of the APOE*3Leiden gene, 
since these mice also express the human APOC1 gene. In 
vitro studies suggest that the function of the apoCl protein 
is related to LPL-mediated lipolysis in the extrahepatic 
circulation . 7,8 However, apoCl may also inhibit the recep- 
tor-mediated uptake of VLDL remnants by the liver. 9"13 
The recent finding that APOC1 transgenic mice display 
hypertriglyceridemia15 sustains these in vitro data but does 
not discriminate between the suggested functions for 
apoC 1, since in these studies in vivo VLDL TG or VLDL 
apoB turnover studies were not performed.
We generated A p o C l-deficient mice to clarify the in 
vivo role of apoC l . 16 However, the data obtained with 
these mice did not accord with an inhibitory effect of 
apoCl on VLDL catabolism. Although lower plasma lipid 
levels were expected in A p o C l-deficient mice, no overt 
effect of apoCl deficiency on plasma lipid levels could be 
observed. We reasoned that the low plasma lipid levels 
usually found in normal mice, which are due to a highly 
efficient lipoprotein metabolism, are already too low to be 
further decreased. We therefore decided to study the role 
of apoCl under conditions of hyperlipidemia in the 
APOE*3Leid&n mice by comparing the formerly described 
APOE*3Leiden-Cl mice with transgenic mice carrying 
only the APO.£*3Leiden gene directly linked to the HCR 
element. The generation of the APOE* 3Leiden-HCR DNA 
construct was made possible by the recent isolation of the 
HCR element by Shachter et al. 17 To discriminate between 
an effect of apoCl on either extrahepatic lipolysis or he­
patic uptake of VLDL, we performed in vivo turnover 
studies using autologous TG-labeled VLDL samples.
In both APO£*3Leiden-Ci and APO£* 3Leiden-HCR 
transgenics the FCR was significantly lower than in the 
control animals. For both transgenic lines the lower FCR 
can only partly be explained by a slightly increased VLDL 
production rate (Table 2). It is obvious from these VLDL 
turnover studies that the actions of apoE* 3 Leiden and 
apoCl in inhibiting the overall in vivo VLDL TG clear­
ance rate are additive. By performing turnover studies in 
functionally hepatectomized animals we were able to show 
that overexpression of the APOC1 gene in addition to the 
APOZs* 3 Leiden gene indeed leads to a further inhibition 
of the hepatic uptake of remnant lipoproteins, since apoCl 
does not affect in vivo lipolysis.
T able  3. Apparent Kinetic Parameters of VLDL for 
LPL-Mediated Lipolysis In Vitro
VLDL
Kun
mmol/L TG
• mux,
mmol • L FFA"1 • min/U LPL“1
E*3L-C1 0.65+0.26 1.00±0.49
E*3L-HCR 0.40±0.05 1,09+0.39
Control 0.59+0.30 0.45+0.17
Values for apparent kinetic parameters for serum VLDL preparations 
(c/<1.006 g/mL) of /*POF3Leiden-C7 (E*3L-C1), /\POP3L8iden-HCR 
(E*3L-HCR), and control mice were calculated from Lineweaver-Burk plots 
and are mean±SD of four independent experiments per VLDL sample.
In vitro experiments9-11 suggest that the inhibitory effect 
of apoC 1 on the hepatic uptake of VLDL remnants is in­
dependent of the amount of apoE present on the particle 
but possibly due to an effect of apoC 1 on the conformation 
of apoE. Other studies suggest that apoCl displaces apoE 
from the particle, thereby decreasing the affinity of the 
particle for the receptor. 12' 14 From our results a displace­
ment of apoE by apoC 1 is not likely to occur (Fig 2).
We have recently generated transgenic mice overexpress­
ing the human APOC1 gene only. Preliminary results show 
that the FI generation of these APOC1 mice are also hy- 
pertriglyceridemic due to a decreased VLDL TG FCR, 
whereas the in vivo lipolysis and production rate are not 
affected (unpublished results). Thus, these results support 
our conclusion that overexpression of APOC1 rather than 
in vivo lipolysis inhibits hepatic uptake of VLDL remnants.
Transgenic mice overexpressing the human APOC2 or 
APOC3 gene are also hypertriglyceridemie. 28,29 In APOC3 
transgenic mice the accumulation of VLDL TGs may be 
due mainly to a decreased ratio of apoE/apoC3 on the 
VLDL particle, leading to a decreased apoE-mediated he­
patic uptake of VLDL. In APOC2 transgenic mice the rel­
ative amount of apoE on the VLDL particle is also de­
creased. As VLDL from these APOC2 transgenic mice is 
less efficient in binding to heparin-Sepharose, it has been 
suggested that in APOC2 transgenic mice VLDL particles 
are less accessible to cell surface-bound LPL, thus leading 
to an inefficient in vivo lipolysis. 30
In addition to an inhibiting effect of apoCl on the he­
patic uptake of VLDL remnants, we also conclude from 
our results that enrichment of VLDL particles with the 
apoE*3Leiden protein results in a disturbed in vivo lipol­
ysis of VLDL TGs. ApoE has an inhibitory effect on the 
LPL catalytic activity. 31 Furthermore, a synthetic peptide 
(residues 139 through 153) corresponding to the receptor- 
binding domain of apoE also inhibits LPL activity. 32 Al­
though apoE*3Leiden differs from apoE by an additional 
repeat of residues 1 2 0  through 126,3 it might still show 
the inhibitory action similar to that described for the syn­
thetic peptide with residues 139 through 153.
Another explanation for the inhibiting of
apoE*3Leiden on in vivo lipolysis might be that 
apoE*3Leiden containing /3-VLDL displays decreased 
binding affinity to heparan sulfate proteoglycans. 33 A de­
creased interaction of apoE*3Leiden VLDL with the ex­
tracellular matrix of endothelial cells would imply a de­
creased accessibility of apoE*3Leiden VLDL to the LPL 
enzyme residing on this matrix, thus resulting in a dis­
turbed in vivo lipolysis of apoE*3Leiden VLDL TGs.
The finding that both isolated apoE*3Leiden VLDLs are 
strongly enriched in apoE protein but do not differ from 
control VLDL in apparent Km value for in vitro LPL lipol­
ysis (using LPL in solution; Table 3) strongly tugues for the
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inability of apoE*3Leiden to bind to proteoglycans as the 
direct cause for the inhibiting effect of the excess of this 
protein on in vivo lipolysis. These results also indicate that 
future studies concerning the suitability of VLDL samples 
as substrate for LPL should be performed in a system in 
which the LPL enzyme is immobilized on, eg, a heparin- 
Sepharose column as described by Clark and Quarfordt. 34 
This will resemble the in vivo situation of VLDL TG li­
polysis much more than the system that is reported in Table 
3. Experiments with immobilized LPL are currently being 
performed with the present VLDL samples.
In conclusion, we showed that excess apoCl on the 
VLDL particle in vivo leads to a further impaired hepatic 
uptake of these particles from the circulation of 
APOE*3heid&n-Cl transgenic mice. In addition, an excess 
of apoE*3Leiden but not apoCl on the VLDL particle 
hampers the in vivo lipolysis of VLDL TGs. Thus, the 
absolute and relative amounts of both apoE and apoCl on 
VLDL particles might be strong factors for the underlying 
metabolic defect in hypertriglyceridemia.
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